Gastric Adenocarcinoma Clinical Trials 2023

What are the top hospitals conducting gastric adenocarcinoma research?

When it comes to clinical trials for gastric adenocarcinoma, the top hospitals are making significant strides in understanding and treating this aggressive form of stomach cancer. Leading the way is M D Anderson Cancer Center in Houston, with five active trials and an impressive 126 total trials dedicated to gastric adenocarcinoma. Since conducting their first trial in 2000, they have been at the forefront of research into this challenging disease. In Bethesda, Maryland, the National Institutes of Health Clinical Center is also actively pursuing advancements in treatment with four ongoing clinical trials and a total of 21 recorded trials since their initial exploration began in 2005.

Meanwhile, Massachusetts General Hospital in Boston has three current gastric adenocarcinoma trials under its belt and an impressive history encompassing 42 past studies dating back to their first recorded trial back in 1998. Memorial Sloan Kettering Cancer Center located in New york City is another prominent institution contributing significantly to combating this condition with three active clinical tests as part of their extensive portfolio comprising a remarkable tally reaching up to106 experiments so far; starting from when they embarked on treating such cases as early as2005.

Even though Sidney Kimmel Comprehensive Cancer Center may appear relatively new compared to others mentioned above; still plays an integral role within this domain by currently running three crucial gastric adenocarcinoma clinical investigations while manifesting dedication towards marking milestones through seven earlier conducted inquiries ever since getting involved only four years ago around2017.

These esteemed hospitals demonstrate a collective commitment toward unravelling the complexities surrounding gastric adenocarcinoma. With each trial conducted and breakthrough achieved, we move closer towards effective treatments that can make a difference for patients fighting against this formidable type of cancer worldwide

Which are the best cities for gastric adenocarcinoma clinical trials?

In the realm of gastric adenocarcinoma clinical trials, several cities have emerged as key players in advancing research. Houston, Texas leads the pack with 13 ongoing trials focused on Pralsetinib, BLU-667, and BLU-451 among others. New york City follows closely behind with 11 active studies investigating treatments like BLU-451, BLU-945, and pralsetinib (BLU-667). Anchorage, Alaska and Denver, Colorado both offer valuable contributions to this field with 8 active trials each that explore treatment options such as mFOLFIRINOX combined with nivolumab. Lastly, Boston also plays a significant role with 6 ongoing trials investigating potential breakthroughs in gastric adenocarcinoma treatment. These cities serve as important hubs for innovative clinical research that aims to improve outcomes for individuals battling this form of cancer.

Which are the top treatments for gastric adenocarcinoma being explored in clinical trials?

Exciting progress is being made in the exploration of clinical trials for gastric adenocarcinoma, with several top treatments capturing attention. Paclitaxel, a long-standing player in the field, stands out with two active trials and an impressive track record of 105 all-time gastric adenocarcinoma trials since its introduction in 1998. Joining the ranks are novel contenders like BLU-451, CT-0508, JNJ-69086420—all currently involved in one active trial each—showcasing their potential against this aggressive cancer. Not to be overlooked is irinotecan, also participating in one ongoing trial and boasting a respectable history of 45 all-time gastric adenocarcinoma trials since debuting back in 2003. As researchers delve deeper into these therapies' efficacy and safety profiles through rigorous clinical investigation, new avenues of treatment may soon open up for patients battling gastric adenocarcinoma worldwide.

What are the most recent clinical trials for gastric adenocarcinoma?

Exciting advancements have emerged in the field of gastric adenocarcinoma, with recent clinical trials offering promising prospects for treatment. Notably, a Phase 2 trial investigated the efficacy of paclitaxel as a potential therapy option. Additionally, another Phase 2 trial examined the effectiveness of an expansion triplet combination to combat this aggressive form of cancer. Furthermore, a Phase 3 study explored Arm I (mFOLFIRINOX and nivolumab) as a potential treatment approach for gastric adenocarcinoma patients. These studies signify significant progress towards improving outcomes and enhancing patient care in the fight against gastric adenocarcinoma.

What gastric adenocarcinoma clinical trials were recently completed?

Several noteworthy clinical trials investigating gastric adenocarcinoma have recently reached completion, reflecting significant progress in the field. The Mayo Clinic concluded a trial in January 2022 evaluating the Colorectal cancer Peptide Vaccine PolyPEPI1018 as a potential treatment option. Additionally, the University of Chicago completed a trial for Pembrolizumab Injection in October 2019, while the National Cancer Institute wrapped up its study on Mesothelin Expression and the University of California, Davis conducted research on Nivolumab, both concluding in August 2019. These trials exemplify ongoing efforts to advance our understanding and treatment options for gastric adenocarcinoma patients.